MedTrace Logo

PK Study in Patients With Parkinson's Disease With IZD174

NCT04338997 · Status: WITHDRAWN · Phase: PHASE1 · Type: INTERVENTIONAL

Last updated 2020-12-04

No results posted yet for this study

Summary

Single center, open-label, intra-individual dose-escalation study in subjects with mild/moderate Parkinson's Disease

Conditions

  • Parkinson Disease

Interventions

DRUG

IZD174

Small molecule inhibitor of NLRP3

Sponsors & Collaborators

  • Inflazome UK Ltd

    lead INDUSTRY

Principal Investigators

  • Teus van Laar, MD, PhD · UMCG Groningen

Study Design

Allocation
NA
Purpose
BASIC_SCIENCE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
45 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-10-31
Primary Completion
2020-11-30
Completion
2020-12-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04338997 on ClinicalTrials.gov